Page 84 - AN-2-2
P. 84

Advanced Neurology                                                    Role of immunosuppressants in autism



            145.  Jeong A, Wong M, 2016, mTOR inhibitors in children:   suppression of natural killer activity and antibody-
                Current indications and future directions in neurology.   dependent cellular cytotoxicity in renal transplant
                Curr Neurol Neurosci Rep, 16: 102.                 recipients. J Clin Immunol, 4: 312–318.
                https://doi.org/10.1007/s11910-016-0708-8          https://doi.org/10.1007/bf00915299
            146.  Berry-Kravis E, Sumis A, Hervey C, et al., 2008, Open-label   151.  Kucuksezer UC, Cetin EA, Esen F, et al., 2021, The role of
                treatment trial of lithium to target the underlying defect in   natural killer cells in autoimmune diseases. Front Immunol,
                fragile X syndrome. J Dev Behav Pediatr, 29: 293–302.   12: 622306.
                https://doi.org/10.1097/dbp.0b013e31817dc447   152.  Nguyen S, Morel V, Le Garff-Tavernier M,  et al., 2006,
            147.  Paribello C, Tao L, Folino A, et al., 2010, Open-label add-on   Persistence of CD16+/CD56-/2B4+ natural killer cells:
                treatment trial of minocycline in fragile X syndrome. BMC   A  highly dysfunctional NK subset expanded in ocular
                Neurol, 10: 91.                                    myasthenia gravis. J Neuroimmunol, 179: 117–125.
                https://doi.org/10.1186/1471-2377-10-91            https://doi.org/10.1016/j.jneuroim.2006.05.028
            148.  Ghosh A, Michalon A, Lindemann L, et al., 2013, Drug   153.  Nived O, Johansson I, Sturfelt G, 1992, Effects of ultraviolet
                discovery for autism spectrum disorder: Challenges and   irradiation on natural killer cell function in systemic lupus
                opportunities. Nat Rev Drug Discov, 12: 777–790.   erythematosus. Ann Rheum Dis, 51: 726–730.
                https://doi.org/10.1038/nrd4102                    https://doi.org/10.1136/ard.51.6.726
            149.  Hasan MS, Ryan PL, Bergmeier LA, et al., 2017, Circulating   154.  McCracken JT, Anagnostou E, Arango C, et al., 2021,
                NK cells and their subsets in Behçet’s disease.  Clin Exp   Drug development for autism spectrum disorder
                Immunol, 188: 311–322.                             (ASD): Progress, challenges, and future directions.  Eur
                https://doi.org/10.1111/cei.12939                  Neuropsychopharmacol, 48: 3–31.
            150.  Prince HE, Ettenger RB, Dorey FJ, et al., 1984, Azathioprine      https://doi.org/10.1016/j.euroneuro.2021.05.010














































            Volume 2 Issue 2 (2023)                         24                         https://doi.org/10.36922/an.391
   79   80   81   82   83   84   85   86   87   88   89